1 of 1
Story summary
- Vitruvias Therapeutics recalled nearly 2,000 bottles of 30 mg thyroid tablets.
- FDA classified the recall as Class I on Sept. 22, 2026.
- Tablets contained 19 µg levothyroxine and 4.5 µg liothyronine, exceeding label strength.
- The excess dose could cause overactive thyroid, weight loss, heat intolerance, fatigue, hypertension, or heart problems.
- Consumers should stop use immediately, contact a healthcare provider, and call Vitruvias at 256-239-9373.